Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06966453 · ClinicalTrials.gov registry record · Phase 1

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

A Phase 1 study of Breast Cancer and Breast Neoplasms, sponsored by Pfizer.

Recruiting
Registry status
Phase 1
Development phase
100
Enrollment target
20
Study locations

NCT06966453 is a Phase 1 study of Breast Cancer and Breast Neoplasms that is actively recruiting participants, run by Pfizer. The registered enrollment target is 100 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06966453, a Phase 1 study of Breast Cancer and Breast Neoplasms, is actively recruiting participants, sponsored by Pfizer.

RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced cancer). This study is seeking participants who: * have breast cancer that is hard to treat and has spread in the body (advanced cancer) * have tumors that have HER2 on them * have received previous treatment for their advanced breast cancer All participants in this study will receive disitamab vedotin at the study clinic once every 2 weeks as an intravenous (IV) infusion (given directly into a vein). Participants will take the study medicine until they or their doctor decides to stop. This might be because their cancer is getting worse, the study medicine is no longer helping, they have bad side effects, or they wish to stop taking the study medicine. During this time, the participants will have study visits every 2 weeks. After the participants have stopped taking the study medicine, they will have follow-up visits about every 6 weeks unless their cancer gets worse. After that, they will have follow-up phone calls about every 12 weeks. The study team will look at the experiences of people receiving the study medicine. This will help the study team decide if the study medicine is safe and effective.

Conditions Studied

Breast Cancer Breast Neoplasms

Interventions

  • DRUG Disitamab vedotin

Study Locations (20)

California

  • Los Angeles Cancer Network - Anaheim
  • Los Angeles Cancer Network - Fountain Valley
  • Los Angeles Hematology Oncology Medical Group - Glendale
  • Los Angeles Cancer Network - Los Angeles
  • Valkyrie Clinical Trials - Los Angeles
  • Mission Community Hospital (Satellite Site) - Los Angeles
  • Clinical and Translational Research Unit (CTRU) - Palo Alto
  • Stanford Cancer Center - Palo Alto
  • Stanford Women's Cancer Center - Palo Alto
  • Stanford Health Care, Investigational Drug Service - Stanford
  • Los Angeles Hematology Oncology Medical Group - Van Nuys

Colorado

  • Rocky Mountain Cancer Centers, LLP - Aurora
  • Rocky Mountain Cancer Centers, LLP - Boulder
  • Rocky Mountain Cancer Centers, LLP - Centennial
  • Rocky Mountain Cancer Centers, LLP - Colorado Springs

Alabama

  • Southern Cancer Center, PC - Daphne
  • Southern Cancer Center, PC - Foley
  • Southern Cancer Center, PC - Mobile

Arizona

  • Banner Gateway Medical Center - Gilbert
  • Banner MD Anderson Cancer Center - Gilbert

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-06-30
Est. Completion 2030-01-27
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06966453

The ClinicalTrials.gov registry entry for NCT06966453 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Disitamab vedotin is the first listed.

NCT06966453 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, Alabama.

Frequently Asked Questions

What is clinical trial NCT06966453 about?

NCT06966453 is a clinical study titled "A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer". The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced cancer). This study is seeking participants who: * have br...

What is the current status of trial NCT06966453?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-06-30. Estimated completion is 2030-01-27.

What conditions does trial NCT06966453 study?

This clinical trial studies the following conditions: Breast Cancer, Breast Neoplasms.

What interventions are being tested in trial NCT06966453?

The interventions under investigation include: Disitamab vedotin (DRUG).

Who is sponsoring clinical trial NCT06966453?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06966453 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Breast Neoplasms

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.